Find patient medical information for Xofigo (radium Ra 223 dichloride) on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings ...

Overall survival was analyzed in real-world patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223.

Find out how to take Radium Ra 223 Dichloride(drug) and its dose. Describes the best time to take the drug and precautions if any that should be followed.

Radium Ra 223 Dichloride(Xofigo) generic is an alpha particle-emitting radioactive therapeutic agent indicated for treatment of patients with metastatic castration-resistant prostate cancer (mCRPC ...

Xofigo ® (radium Ra 223 dichloride) injection granted Marketing Authorization in the European Union. Oslo, Norway, 15 November 2013 - Algeta ASA (OSE: ALGETA) announces today that Bayer has ...

OSLO, NORWAY--(Marketwired - May 15, 2013) - Intended for US Media only * Algeta to host international conference call scheduled for tomorrow at 08:00 CET, 02:00 Eastern time - details below Oslo ...

CASE-history data are presented on 12 women who have carried in their skeletons for many years toxicologically interesting burdens of the radioisotopes Ra226 (radium, or Ra) and Ra228 (mesothorium, ...

Xofigo® (radium Ra 223 dichloride) Injection Recommended for Approval in the European Union Oslo, Norway, 20 September 2013 - Algeta ASA (OSE: ALGETA), announced today that Bayer has received a ...

Bayer Healthcare announced that the FDA has accepted its New Drug Application (NDA) for filing and has granted priority review of Radium Ra 223 Dichloride (radium-223) for the treatment of ...

An official from Bayer, whose radium Ra 223 dichloride (Xofigo) was approved in 2013 to treat patients with CRPC and symptomatic bone metastases, 5 told Evidence-Based Oncology (EBO) in a February ...